Dublin, July 16, 2024 (GLOBE NEWSWIRE) -- The "United States Hereditary Angioedema Therapeutics Market, By Region, Competition, Forecast and & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.
The United States Hereditary Angioedema (HAE) Therapeutics Market has reached a significant milestone, valued at USD 846.80 million in 2023 with expectations for a steadfast growth projecting a CAGR of 7.12% through 2029. As a fundamental component of the American healthcare system, the HAE therapeutics sector addresses the pressing need for effective treatments for this rare, potentially fatal genetic condition, which triggers severe swelling across various body parts.
Several factors contribute to the HAE market's robust growth trajectory. Among them, advancements in medical research and drug development lead the way, with novel therapies providing groundbreaking management approaches for this chronic disorder. With heightened awareness, improved diagnostic practices, and a steady patient population increase, the market outlook remains optimistic. Patients now benefit from a broader array of treatment options, including subcutaneous and oral routes, which have significantly improved their quality of life.
Breakthrough Therapies Revolutionizing Treatment Approaches
The U.S. Hereditary Angioedema Therapeutics sector celebrates the FDA's approval of innovative treatments offering both prophylactic and acute solutions against the distressing symptoms of HAE. These market advancements are providing patients with effective management strategies, thus ensuring substantial cost savings by reducing hospitalizations and streamlining resource allocation within the healthcare industry.
Challenges to Market Growth
Despite substantial progress, the U.S. HAE Therapeutics Market faces significant challenges, primarily concerning the high cost of HAE treatment. These costs pose accessibility barriers, impacting the quality of care for patients. Additionally, maintaining long-term treatment adherence is a challenge that the industry must continually address.
Emerging Trends in Hereditary Angioedema Therapeutics
The advent of advanced monoclonal antibodies suggests a promising shift in HAE management, with these therapies offering extended protection and reduced treatment frequencies. Furthermore, early diagnosis through genetic testing has become a focal point in improving patient outcomes, allowing for more personalized and effective treatment regimens.
Insights on Market Segments
In 2023, C1-esterase inhibitors dominate the treatment segment, valued for their established efficacy. Subcutaneously administered therapies lead the route of administration, appreciated for their convenience and contribution to increased patient compliance. Region-wise, the Mid-West secures its position as the principal market due to a concentrated pool of patients and a robust healthcare infrastructure.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 82 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $846.8 Million |
| Forecasted Market Value (USD) by 2029 | $1267.15 Million |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | United States |
A selection of companies mentioned in this report includes, but is not limited to:
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Seqirus Pty Ltd. (CSL Limited)
- Attune Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Pharming Healthcare N.V.
- Sanofi AG
- Cipla Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/gy08oc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
